AR055580A1 - Uso de leucocidina de panton valentine para el tratamiento y prevencion de infecciones por estafilococos - Google Patents
Uso de leucocidina de panton valentine para el tratamiento y prevencion de infecciones por estafilococosInfo
- Publication number
- AR055580A1 AR055580A1 ARP060102502A ARP060102502A AR055580A1 AR 055580 A1 AR055580 A1 AR 055580A1 AR P060102502 A ARP060102502 A AR P060102502A AR P060102502 A ARP060102502 A AR P060102502A AR 055580 A1 AR055580 A1 AR 055580A1
- Authority
- AR
- Argentina
- Prior art keywords
- pvl
- subunit
- aureus
- panton
- infections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Composiciones y métodos para tratar infecciones por Staphylococcus aureus (S. aureus). En particular, se proveen vacunas que comprenden un antígeno de Leucocidina de Panton Valentine (PVL), anticuerpos que se unen a un antígeno de PVL y composiciones que los contienen, métodos para preparar tales composiciones y métodos para tratar infecciones por S. aureus, entre las que se incluyen las infecciones resistentes a la meticilina adquiridas en la comunidad. También se proveen anticuerpos de PVL, que incluyen anticuerpos de PVL específicos para una subunidad PVL determinada, y antígenos de la PVL, que incluyen antígenos de PVL conjugados y mutados. Reivindicacion 1: Un anticuerpo que se une específicamente a un antígeno de leucocidina de Panton-Valentine (PVL) de S. aureus, seleccionado del grupo formado por (i) un anticuerpo que se une específicamente a una subunidad LukF-PV pero no se une específicamente a una subunidad LukS-PV y (ii) un anticuerpo que se une específicamente a una subunidad LukS-PV pero no se une específicamente a una subunidad LukF-PV.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68952605P | 2005-06-13 | 2005-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055580A1 true AR055580A1 (es) | 2007-08-29 |
Family
ID=37440793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102502A AR055580A1 (es) | 2005-06-13 | 2006-06-13 | Uso de leucocidina de panton valentine para el tratamiento y prevencion de infecciones por estafilococos |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090074755A1 (es) |
EP (2) | EP1915396A2 (es) |
JP (1) | JP5096326B2 (es) |
KR (1) | KR101302764B1 (es) |
CN (2) | CN101218252A (es) |
AR (1) | AR055580A1 (es) |
AU (1) | AU2006257774B2 (es) |
CA (1) | CA2611023A1 (es) |
MX (1) | MX2007015758A (es) |
NZ (1) | NZ565069A (es) |
TW (1) | TWI374892B (es) |
WO (1) | WO2006135912A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006076058A1 (en) * | 2005-01-10 | 2006-07-20 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
CA2642984A1 (en) * | 2006-02-22 | 2007-09-07 | The Texas A & M University System | Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use |
US20180221466A9 (en) * | 2006-06-12 | 2018-08-09 | Glaxosmithkline Biologicals S.A. | Use of alpha-toxin for treating and preventing staphylococcus infections |
CN101466406B (zh) * | 2006-06-12 | 2012-06-27 | 葛兰素史密斯克蓝生物品公司 | α-毒素在治疗和预防葡萄球菌感染上的用途 |
JP2008013447A (ja) | 2006-07-03 | 2008-01-24 | Juntendo | 毒素検出方法 |
FR2912219A1 (fr) * | 2007-02-06 | 2008-08-08 | Biomerieux Sa | Procede de diagnostic in vitro des staphylococcus aureus producteurs de pvl, anticorps monoclonaux et kits de diagnostic |
US8936791B2 (en) | 2006-10-18 | 2015-01-20 | Biomerieux | Method for in vitro diagnosis of PVL-producing Staphylococcus aureus |
WO2010036958A1 (en) * | 2008-09-25 | 2010-04-01 | Cedars-Sinai Medical Center | Methods of treatment for mrsa infections |
CN103025352B (zh) | 2010-05-05 | 2017-07-11 | 纽约大学 | 金黄色葡萄球菌杀白细胞素及其治疗组合物和用途 |
US9316640B2 (en) * | 2011-11-11 | 2016-04-19 | Alere San Diego, Inc. | Devices and methods for detection of Panton-Valentine Leukocidin (PVL) |
KR101999299B1 (ko) | 2011-12-02 | 2019-07-12 | 인티그레이티드 바이오쎄라퓨틱스, 인크. | 팬턴-발렌타인 류코시딘(pvl) 유래 폴리펩티드를 포함하는 면역원성 조성물 |
US10781246B2 (en) | 2015-06-05 | 2020-09-22 | New York University | Compositions and methods for anti-staphylococcal biologic agents |
CN107224575B (zh) * | 2017-03-06 | 2018-11-09 | 浙江海隆生物科技有限公司 | 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用 |
CN107224576A (zh) * | 2017-03-06 | 2017-10-03 | 浙江海隆生物科技有限公司 | 奶牛金黄色葡萄球菌乳房炎亚单位的疫苗及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327082A (en) * | 1979-07-12 | 1982-04-27 | Adcock-Ingram Laboratories Limited | Mastitis vaccination |
AU681573B2 (en) | 1991-11-22 | 1997-09-04 | Glaxosmithkline Biologicals Sa | Type I and type II surface antigens associated with (staphylococcus epidermidis) |
US5770208A (en) | 1996-09-11 | 1998-06-23 | Nabi | Staphylococcus aureus B-linked hexosamine antigen |
US6294177B1 (en) | 1996-09-11 | 2001-09-25 | Nabi | Staphylococcus aureus antigen-containing whole cell vaccine |
US6703025B1 (en) * | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
WO2000015238A1 (en) | 1998-09-14 | 2000-03-23 | Nabi | COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV |
JP2000316574A (ja) * | 1999-03-10 | 2000-11-21 | Matsushita Seiko Co Ltd | Mrsaが産生する毒素タンパクの検出方法およびモノクローナル抗体とその断片およびmrsaが産生する毒素タンパク検出用キットおよびモノクローナル抗体を産生するハイブリドーマ |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
GB0126266D0 (en) * | 2001-11-01 | 2002-01-02 | Microbiological Res Authority | Anthrax antigenic compositions |
DE602004024179D1 (de) * | 2003-03-31 | 2009-12-31 | Intercell Ag | Staphylococcus epidermidis antigene |
US20060134141A1 (en) * | 2004-12-14 | 2006-06-22 | Nabi Biopharmaceuticals | Glycoconjugate vaccines containing peptidoglycan |
WO2006076058A1 (en) * | 2005-01-10 | 2006-07-20 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
CN101466406B (zh) * | 2006-06-12 | 2012-06-27 | 葛兰素史密斯克蓝生物品公司 | α-毒素在治疗和预防葡萄球菌感染上的用途 |
-
2006
- 2006-06-13 JP JP2008516037A patent/JP5096326B2/ja not_active Expired - Fee Related
- 2006-06-13 NZ NZ565069A patent/NZ565069A/en not_active IP Right Cessation
- 2006-06-13 AU AU2006257774A patent/AU2006257774B2/en not_active Ceased
- 2006-06-13 MX MX2007015758A patent/MX2007015758A/es active IP Right Grant
- 2006-06-13 CA CA002611023A patent/CA2611023A1/en not_active Abandoned
- 2006-06-13 US US11/451,608 patent/US20090074755A1/en not_active Abandoned
- 2006-06-13 EP EP06784845A patent/EP1915396A2/en not_active Ceased
- 2006-06-13 EP EP10180402A patent/EP2289938A3/en not_active Withdrawn
- 2006-06-13 CN CNA2006800246819A patent/CN101218252A/zh active Pending
- 2006-06-13 AR ARP060102502A patent/AR055580A1/es unknown
- 2006-06-13 WO PCT/US2006/023062 patent/WO2006135912A2/en active Application Filing
- 2006-06-13 CN CN2012101415012A patent/CN102698261A/zh active Pending
- 2006-06-13 KR KR1020087000858A patent/KR101302764B1/ko not_active IP Right Cessation
- 2006-06-13 TW TW095121049A patent/TWI374892B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP5096326B2 (ja) | 2012-12-12 |
CN101218252A (zh) | 2008-07-09 |
NZ565069A (en) | 2011-08-26 |
MX2007015758A (es) | 2008-02-22 |
EP2289938A3 (en) | 2011-04-06 |
WO2006135912A3 (en) | 2007-05-24 |
TWI374892B (en) | 2012-10-21 |
AU2006257774B2 (en) | 2012-03-01 |
KR101302764B1 (ko) | 2013-09-02 |
EP1915396A2 (en) | 2008-04-30 |
CA2611023A1 (en) | 2006-12-21 |
JP2008546648A (ja) | 2008-12-25 |
AU2006257774A1 (en) | 2006-12-21 |
US20090074755A1 (en) | 2009-03-19 |
KR20080016956A (ko) | 2008-02-22 |
EP2289938A2 (en) | 2011-03-02 |
WO2006135912A2 (en) | 2006-12-21 |
TW200716670A (en) | 2007-05-01 |
CN102698261A (zh) | 2012-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055580A1 (es) | Uso de leucocidina de panton valentine para el tratamiento y prevencion de infecciones por estafilococos | |
AR078470A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
CL2022000328A1 (es) | Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017) | |
CL2021000293A1 (es) | Anticuerpos anti-trem2 y métodos relacionados (divisional de solicitud no.202001575) | |
CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
CL2021002994A1 (es) | Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067) | |
AR059688A1 (es) | Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus | |
WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
PE20210115A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
PE20110797A1 (es) | Anticuerpos anti mn | |
CU20170169A7 (es) | Anticuerpos de factor xi | |
PE20061040A1 (es) | Anticuerpos antiamiloides humanizados | |
AR068862A1 (es) | Terapia de combinacion de un anticuerpo anti- cd20 de tipo ii con un agente activo anti- bcl-2 | |
AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
AR091961A1 (es) | Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b) | |
BRPI0519232A2 (pt) | vacinas de conjugados de sacarÍdeos | |
AR078601A1 (es) | Composiciones inmunogenicas de antigenos de staphylococcus aureus | |
AR077756A1 (es) | Anticuerpos especificos para bacterias gram-positivas | |
BR112017011478A2 (pt) | composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante | |
CL2021001541A1 (es) | Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal (divisional de la solicitud no. 201900694) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |